Clinical Trial: NCT05015608
Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Hutchison Medipharma Limited |
| Information Provided By: | Hutchmed |
| Last Update Posted: | 2026-05-27 |
Study Overview
Brief Summary
This study will look at how effective the study drug(Savolitinib combined with Osimertinib) versus Pemetrexed combined with platinum in treatment of patients with locally advanced or metastatic NSCLC with MET amplification after failure of the first-line EGFR inhibitor therapy.
Official Title
Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET Amplification
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Savolitinib + Osimertinib
- Drug: Pemetrexed + Cisplatin /Carboplatin
Other Study ID Numbers
- 2020-504-00CH3
Start Date (Actual)
2021-11-22
Primary Completion Date (Actual)
2025-08-22
Study Completion Date (Actual)
2025-08-22
Enrollment (Actual)
216
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Hutchison Medipharma Limited |
| Information Provided By: | Hutchmed |
| Last Update Posted: | 2026-05-27 |
Study Overview
Brief Summary
This study will look at how effective the study drug(Savolitinib combined with Osimertinib) versus Pemetrexed combined with platinum in treatment of patients with locally advanced or metastatic NSCLC with MET amplification after failure of the first-line EGFR inhibitor therapy.
Official Title
Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET Amplification
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Savolitinib + Osimertinib
- Drug: Pemetrexed + Cisplatin /Carboplatin
Other Study ID Numbers
- 2020-504-00CH3
Start Date (Actual)
2021-11-22
Primary Completion Date (Actual)
2025-08-22
Study Completion Date (Actual)
2025-08-22
Enrollment (Actual)
216
Study Type
Interventional
Phase
Phase 3